April 13, 2022 4:56pm

On Thursday, the holiday-shortened week will end this week’s session

Pre-open indications: 2 HITs 2 MISS and 1 Pimp/Pump/Promote

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?

If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.


The Dow closed UP +344.23points (+1.01%); the S&P closed UP +49.14 points (+1.12%) while the Nasdaq closed UP +272.02 points (+2.03%)



Indexes rose on Wednesday as earnings season kicked off and traders ignored surging inflation numbers.


Pre-open post: RegMed Investors’ (RMi) pre-open: tread lightly by measuring and analyzing sector equities carefully by reducing exposure in risky assets; consider some issues, cash positions (runways), grant and collaborator revenue, institutional investor/retail and management holdings, advancing trials and finally a lean G&A.”https://www.regmedinvestors.com/articles/12386


RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Wednesday opened positive at 29 up/4 downs, 2 flats, stayed positive at the mid-day at 33/1 and 1 flat, ending with a positive close of 3/32


Pre-open Indications: 2 HITs: < Beam Therapeutics (BEAM +$1.45), CRISPR Therapeutics (CRSP +$1.29)> 2 MISS < Intellia Therapeutics (NTLA +$1.65), Global Blood Therapeutics (GBT +$1.06)> 1 Pimp/Pump/ Promote <Biostage (BSTG +$0.50 with 2,851 shares traded)>


Key Metrics:

  • Wednesday - Sector volume was LOW with 3 of the 32-upside having higher than the 3-month average volume with LOW volume of 1 of 3-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB was up +2.53% and the XBI was up +3.28%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -2.44 points or -10.06% at 21.82


Jumping with share pricing momentum (10 of 32):

  • Alnylam Pharmaceuticals (ALNY +$8.88 after Tuesday’s +$2.12 and Monday’s -$5.99),
  • Ultragenyx (RARE +$3.74 after Tuesday’s +$1.34 and Monday’s -$2.62),
  • Fate Therapeutics (FATE +$1.99 after Tuesday’s +$0.61 and Monday’s -$2.15),
  • Vericel (VCEL +$1.83 after Tuesday’s -$0.61 and Monday’s -$0.51),
  • Intellia Therapeutics (NTLA +$1.65 after Tuesday’s -$0.62 and Monday’s -$1.33),
  • uniQure NV (QURE +$1.50 after Tuesday’s -$0.13 and Monday’s +$0.08),
  • Beam Therapeutics (BEAM +$1.45 after Tuesday’s +$0.43 and Monday’s -$2.76),
  • CRISPR Therapeutics (CRSP +$1.29 after Tuesday’s +$2.13),
  • Global Blood Therapeutics (GBT +$1.06 after Tuesday’s +$0.68),
  • Ionis Pharmaceuticals (IONS +$1.01),

Hammered in today’s market (3 of 3):

  • MiMedx (MDXG -$0.29 after Tuesday’s +$0.105),
  • BioLife Solutions (BLFS-$0.23 after Tuesday’s -$0.92 and Monday’s -$0.38),
  • Homology Medicine (FIXX -$0.09),


April, Q2/2022:

Wednesday closed positive with 32incliners and 3 decliners



Thank algorithms and electronic trading today ...

Earnings’ season is upon us as AxoGen (AXGN) announces May 4th as their release.

After the worst session in more than a while, the oversold were recognized by electronic trading and algorithms after undervaluation.

As I stated in last Friday night’s post, “What justifies the share pricing, it’s NOT investor advocacy?  The short-term and near-term pricing “shades” the long-term price targets.”

Volume again was also barely there … as many companies prepare for a Q1/22 response to earnings – and it might get even more ugly.

I am more than worried about investment bank pricey analyst valuations that (in my mind’s eye) have NO basis.

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.